
Adapalene: Prevents clogged pores and treats inflammatory and non-inflammatory acne. Cysteamine: Can reduce melasma pigmentation in tested topical formulas.


Choose for clogged pores and ongoing acne prevention; introduce gradually.
Consider for diagnosed melasma when a suitable topical option is needed.
Can you use both?
Both can irritate. Cysteamine is a short-contact cream; keep it and adapalene on different times of day and build up slowly.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.










Binds retinoid receptors: Adapalene works without conversion to retinoic acid. Helps keep follicles clear: Regulates cell shedding and inflammatory pathways.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Affects melanin formation: Cysteamine acts through several pigment pathways. May help melasma: The formula, contact time and tolerance matter.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Adapalene is a medicine, not a cosmetic retinol. U.S. acne formulations include 0.1% and 0.3%; the higher strength is prescription.
0.1%
0.3%
OTC acne gel
A labeled acne treatment in the U.S. Improvement takes time; using extra product does not speed the result.
Prescription acne gel
A higher-strength formulation with comparative trial evidence. A clinician can weigh benefit against irritation.
Choosing a strength: Choose the medicine and vehicle for acne severity and tolerance. Adapalene percentages are not equivalent to retinol or retinaldehyde percentages.
Higher strengths: Dryness, peeling and irritation can occur. Do not step up strength or combine several retinoids just because improvement is slow.
Formula matters: Products combining adapalene with benzoyl peroxide have additional active ingredients and different labeling; read the whole product name.
5% cysteamine cream is the main concentration studied for melasma. Contact time is product-specific; some studied formulas are short-contact treatments rather than overnight creams.
5%
Studied melasma cream
Controlled trials studied this strength. One short-contact trial used a specific cream; follow the current product’s instructions rather than copying a study schedule.
Choosing a strength: Choose a finished topical product with clear instructions for how long to leave it on and when to rinse.
Higher strengths: There is no established benefit from escalating beyond the studied strength. Burning, redness or a persistent rash are reasons to stop and reassess.
Formula matters: Stabilization, the base cream and exposure time affect tolerability. Different cysteamine formulations need not have identical instructions.
Approximate windows, not promises.
First few weeksDryness or irritation may occur; worsening is not required for benefit.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksFewer new lesions may become noticeable.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksReassess acne control after a consistent course.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsMaintenance may help if the treatment works and remains comfortable.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsContinue only if appropriate; scarring or persistent acne warrants reassessment.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
Dryness, stinging and peeling can occur, especially early in use.
Odour, stinging and irritation may limit use; follow wash-off instructions.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Follow the age and use restrictions on the label; OTC adapalene 0.1% is labelled for ages 12 and older in the US.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Retinoids are avoided in pregnancy and while trying to conceive.
Data in pregnancy are limited; ask the clinician managing your pregnancy before using.
On the skin. The finished product delivers adapalene in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. Binds retinoid receptors directly; it does not need conversion into retinoic acid.
Skin response. Binds retinoid receptors directly, regulating follicular cell shedding and inflammatory pathways.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers cysteamine in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Acts on pigment-related pathways; the cream, contact time and tolerance influence its practical effect.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Choose for clogged pores and ongoing acne prevention; introduce gradually.
Guidelines and controlled acne trials support adapalene. Evidence for acne medicines should not be transferred automatically to retinol, and irritation does not indicate greater benefit.
Consider for diagnosed melasma when a suitable topical option is needed.
A small placebo-controlled study supports 5% cream over four months. Active-comparator studies are small and do not prove equal efficacy to hydroquinone. The mass shown refers to the free base, not its hydrochloride salt.
Sources